Testing effectiveness (Phase 2)Study completedNCT00523848
What this trial is testing
Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Roswell Park Cancer Institute 46